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To evaluate the prognostic value of the expression of the mixed lineage leukemia (MLL) gene for predicting
the relapse of patients with MLL-rearranged acute leukemia (AL) after allogeneic hematopoietic stem cell
transplantation (allo-HSCT), the levels of MLL transcripts in bone marrow (BM) specimens were monitored
serially by real-time quantitative polymerase chain reaction (RQ-PCR) at predetermined time points in 40
patients with MLL-rearranged AL who were treated with allo-HSCT. These patients were followed for a
median of 24.5 months (range, 8 to 60 months). A total of 236 BM samples were collected and analyzed. Of
these, 230 were monitored concurrently for minimal residual disease (MRD) by ﬂow cytometry (FCM) for
leukemia-associated aberrant immune phenotypes and by RQ-PCR for the expression of the Wilms tumor
(WT1) gene. The 3-year cumulative incidence of relapse in patients who experienced MLL-positive patients
(MLL > .0000%) (n ¼ 9) after HSCT was 93.5% (95% conﬁdence interval [CI], 87% to 100%) compared with 12.5%
(95% CI, 5.6% to 19.4%) for MLL-negative patients (n ¼ 31) (P < .001). For these 2 patient groups, the 3-year
overall survival (OS) was 12.5% (95% CI, .8% to 24.2%) and 77.8% (95% CI, 68.4% to 87.2%) (P < .001), respec-
tively, and the 3-year leukemia-free survival (LFS) was 0% and 72.2% (95% CI, 61.1% to 83.3%), respectively
(P < .001).MLL positivity was associated with a higher rate of relapse (hazard ratio [HR], 18.643; 95% CI, 3.449
to 57.025; P ¼ .001), lower LFS (HR, 7.267; 95% CI, 2.038 to 25.916; P ¼ .002), and lower OS (HR, 8.259; 95% CI,
2.109 to 32.336; P ¼ .002), as determined by Cox multivariate analysis. The expression of the MLL gene had a
higher speciﬁcity and sensitivity than WT1 or MRD monitored by FCM for predicting the relapse of the pa-
tients withMLL þ AL. Our results suggest that monitoring the expression of theMLL gene may help to identify
patients with MLL þ AL who are at high risk of relapse after allo-HSCT and may provide a guide for suitable
intervention.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The structural abnormality of the chromosomal band
11q23 (11q23þ) bearing the translocation of the mixed
lineage leukemia (MLL) gene is a recurrent chromosomal
rearrangement observed in 3% to 4% of patients with acute
myeloid leukemia (AML) and 3% to 7% of patients with acute
lymphoblastic leukemia (ALL) [1,2]. AML with t (9;11) was
determined to be in the intermediate risk category by the
National Comprehensive Cancer Network, whereas cases
with other balanced 11q23 translocations were found to have
an unfavorable risk, with relapse rates reported of 47% to
100% and overall survival of 0% to 45% [3,4]. ALL with
balanced 11q23 translocations is also considered to be highdgments on page 935.
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14.03.008risk and has a reported overall survival of 20% to 29% in most
large multicenter studies [5-7]. The long-term survival of
patients has remained poor due to a high rate of relapse with
chemotherapy alone [3-7].
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is 1 of the curative therapies currently available
for acute leukemia (AL). In a prospective, multicenter cohort
study conducted in 2012, we demonstrated that the outcome
of patients with MLLþ leukemia undergoing allo-HSCT
compared favorably with that observed in various studies
with chemotherapy alone and showed that allo-HSCT could
be a valuable choice of treatment for patients with MLLþ AL
[8]. However, the relapse rate at 3 years was still 25.3% (95%
CI, 12.7% to 37.9%). The early detection of relapse by moni-
toring minimal residual disease (MRD) is useful for guiding
appropriate interventions that could aid in prevention
of hematological relapse. For subtypes of AL with speciﬁc
biomarkers, such as BCR/ABL and AML1/ETO, the expressed
fusion gene can be used for monitoring MRD. Because MLL
is a recurrent chromosomal rearrangement in AL, weTransplantation.
J. Liu et al. / Biol Blood Marrow Transplant 20 (2014) 929e936930hypothesized that the expression of the ML gene could be
useful for predicting early recurrence in patients with MLLþ
AL after allo-HSCT. To date, most studies have focused on the
prognostic value of MLL during induction or consolidation
therapy, and no studies have examined the impact of moni-
toring MLL expression before and after HSCT. Therefore, we
conducted a prospective cohort to investigate whether a
quantitative evaluation of MLL expression could provide a
useful method for monitoring early relapse of MLLþ AL after
allo-HSCT. We found that the incidence of leukemia relapse
after transplantationwas signiﬁcantly higher in patients with
detectableMLL expression after the secondmonth afterHSCT.
METHODS
Patients
Between October 2007 and October 2012, 40 consecutive patients
diagnosed with MLLþ AL undergoing allo-HSCT at the Peking University
People’s Hospital, Institute of Hematology were enrolled. These patients
were part of a multicenter clinical trial, registered at www.chictr.org as #
ChiCTR-ONC-12002739, the clinical outcome of which was previously re-
ported in 2013 [8]. These 40 patients who were treated at our hospital were
monitored sequentially forMLL expression and were enrolled in the current
cohort. The patients’ data were updated until November 30, 2013. The in-
clusion and exclusion criteria were identical to those for the previous trial
[8]. The institutional review board at the hospital approved the protocol, and
all patients or their guardians signed consent forms approved by the insti-
tutional review board.
Donor Selection and Transplantation Protocols
A matched sibling donor was chosen as a ﬁrst treatment option. A
suitable, closely HLA-matched unrelated donor, speciﬁcally with more than
8 of 10 matching HLA-A, B, C, DR, DQ loci and 5 of 6 or 6 of 6 matching HLA-
A, B, DR loci, was the second choice. Patients were eligible for haploidentical
stem cell transplantation if a matched sibling donor or a suitable, closely
HLA-matched unrelated donor was unavailable or if there was insufﬁcient
time for an unrelated donor search because of disease status. The donors and
patients were assessed for degree of HLAmatching. HLA-A and HLA-B typing
was performed by intermediate resolution DNA typing, and HLA-DRB1
typing was performed using high-resolution DNA techniques. All patients
in this study received myeloablative conditioning regimens. The condi-
tioning therapy for patients undergoing haploidentical or unrelated HSCT
was as previously reported [8,9]
Sample Preparation
Bone marrow (BM) samples from patients were obtained to assess MRD
after HSCT. TheMRD time points that wemonitored included at time of allo-
HSCT; 1 month, 2 months, 3 months, 4 months, 6 months, 9 months, and
12 months after allo-HSCT; and every 6 months thereafter to the deﬁned
endpoints or for at least until 1 year after transplantation. More frequent
MRD monitoring was carried out in some patients, depending on their in-
dividual disease status.Table 1
Clinical Characteristics of the Patients with MLLþ AL Who Received Allo-HSCT
Characteristic All Patients
No. of patients 40
Age, median (range), yr 27 (2-53)
Sex (male:female), % 46:54
Underlying disease (AML:ALL), % 42:58
Pretransplantation disease status (CR1:Non-CR1), % 88:12
MLL fusion partners (9p22:4q21:6q22:10p12:17q21:19p13:
complex karyotype)
9:16:6:4:1:2:3
Donor type (HLA identical:unrelated:HLA haploidentical), % 10:15:75
ABO compatibility (compatible: incompatible), % 54:36
WBC at diagnosis (less than 30:30 or more),  109/L, % 58:43
Infused nuclear cells, median (range),  108/kg 7.88 (.4-11.13)
Infused CD34þ cells, median (range),  106/kg 2.21 (.81-6.19)
Diagnosis to transplantation interval, median (range), d 180 (100-900)
Prophylactic DLI, n 6
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CR1, ﬁrs
count; DLI, donor lymphocyte infusion; d, day; Allo-HSCT, allogeneic hematopoieticRQ-PCR
Mononuclear BM cells were obtained by Ficoll Hypaque density gradient
centrifugation. TRIzol reagent (Invitrogen, Carlsbad, CA) was used to extract
total RNA according to the manufacturer’s instructions. Random hexamer
primers andMoloneymurine leukemia virus reverse transcriptasewere used
to transcribe RNA into cDNA. We used Taqman-based RQ-PCR technology,
and all PCR reactions and ﬂuorescence measurements were performed using
an ABI PRISM 7500 real-time PCR system (PE Applied Biosystems, Foster City,
CA). We selected ABL as a control gene to compensate for variation in quality
and quantity of the RNA and cDNA. The primers and probe for ABL were
based on a report from the Europe Against Cancer Program [10,11]. MLL
fusion transcripts were ampliﬁed as described previously [12-14]. Each PCR
run included a negative control (H2O), a positive control, and a set of serial
dilutions of ABL plasmids. The construction of ABL plasmid calibrators was
performed as previously described [15]. Any sample with< 3 104 copies of
ABL was regarded as poor quality and was excluded from the test. The ex-
periments were performed in duplicate. The transcript level was calculated
as a percentage of the target transcript copies to ABL copies.
Flow Cytometry
MRD detected by 4-color ﬂow cytometry (FCM) was previously
described [16,17]. Leukemia-associated immunophenotype were identiﬁed
in diagnostic BM specimens and marker combinations that allowed detec-
tion of 1 leukemia cell per 1000 mononuclear BM cells were applied to
subsequent samples.
Donor Lymphocyte Infusion
Modiﬁed donor lymphocyte infusion (DLI)was administered to 2 patients
without acute graft-versus-host disease (GVHD) who showed evidence of
recipient chimerism or MRD detected by molecular or cytogenetic methods
after a trial of immunosuppressantwithdrawal [18]. ThemodiﬁedDLI regimen
consisted of granulocyte-colony stimulating factoreprimed peripheral blood
stem cells, instead of harvested nonprimed donor lymphocytes, and short-
term immunosuppressive agents [19]. Prophylactic DLI was administered to
a total of 6 patients between day 28 and day 60 after transplantation. The 3
patientswithnonremission statuswhowere identiﬁed tohave averyhigh risk
of leukemia relapse in the case of GVHD absence [20] received prophylactic
DLI, and the other 3 patients who underwent transplantation in complete
remission (CR) received prophylactic DLI at the physician’s discretion.
Deﬁnitions and Assessments
DetectableMLL expression at any level (MLL> .0000%)was deﬁned asMLL
positive in this study. The day of engraftment was deﬁned as the ﬁrst day of 3
consecutive post-transplantation days onwhich the absolute neutrophil count
(ANC) exceeded 500/mL. Patients who survived at least 28 days were consid-
ered to have had successful engraftment. The criteria for grading acute GVHD
(aGVHD) and chronic GVHD (cGVHD) have been previously published [21,22].
CR was deﬁned as hematological CR; that is, < 5% BM blasts, the absence of
blasts in peripheral blood, the absence of extramedullary disease, an ANC
> 1.0 109/L, and a platelet count> 100 109/L with no red cell transfusions.
Relapse was deﬁned by morphologic evidence of disease in the peripheral
blood, marrow, or extramedullary sites. Chimerismwas evaluated in recipient
peripheral blood cells by FISH. When the patient and donor were of the same
sex, chimerism was assessed by using PCR-based analyses of polymorphic
minisatellite or microsatellite regions (short tandem repeats [STRs]).MLL before Transplantation MLL after Transplantation
Negative Positive Negative Positive
24 11 31 9
27 (2-53) 25 (2-41) 25 (2-53) 29 (12-51)
50:50 37:63 45:55 45:55
35:45 55:45 39:61 44:56
95:5 64:36 97:3 56:44
8:11:2:3:0:2:2 1:5:4:1:1:0:0 8:12:4:3:0:0:2 1:4:2:1:1:2:0
9:21:70 11:10:79 10:16:74 10:14:76
55:45 53:37 54:36 54:36
54:46 54:46 55:45 57:43
7.88 (.4-10.35) 7.36 (1.2-11.13) 7.92 (.4-11.13) 7.65 (2.7-10.46)
3.42 (1.2-6.19) 2.06 (.81-5.99) 2.21 (9.81-6.19) 2.43 (1.2-5.73)
143 (100-324) 189 (121-900) 143 (100-277) 192 (121-900)
2 4 3 3
t complete remission; HLA, human leukocyte antigen;WBC, white blood cell
stem cell transplantation;MLL, mixed lineage leukemia; AL, acute leukemia.
Figure 1. (A) Rate of relapse based on MLL expression at the time of allo-HSCT
(P < .001). (B) Leukemia-free survival based on MLL expression at the time of
allo-HSCT (P < .001). (C) Overall survival based on MLL expression at the time
of allo-HSCT (P < .001).
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The primary endpoint studied was relapse rate and the secondary
endpoint was survival. The event for overall survival (OS) was death
(regardless of the cause). The events for leukemia-free survival (LFS)
included death in CR or relapse. The reference date of November 30, 2013
was used to deﬁne the end of follow-up.
Summary statistics, such as proportions, means, standard deviations,
medians, and ranges, were used to describe the patient characteristics,
pretransplantation variables, and outcomes. The associations between MLL
expression and post-transplantation outcomes were analyzed by the
Kaplan-Meier method or calculated using cumulative incidence curves to
accommodate competing risks. The competing risk for engraftment was
death without engraftment; the competing risks for GVHD were death
without GVHD, relapse, and graft rejection; relapse was a competing risk for
nonrelapse mortality (NRM); and NRM was a competing risk for relapse.
Differences in relapse, transplantation-related mortality (TRM), LFS, and OS
between groups were calculated using the log-rank test. A 2-sided P value of
.05 was regarded as signiﬁcant. To test the independence of relapse-
predicting factors, multivariate Cox regression analysis was applied. The
independence of categorical parameters was calculated using the chi-square
test or Fisher exact test, and the distribution of continuous variables was
calculated using the Mann-Whitney U-test. All statistical analyses were
performed using SPSS 19.0 software (SPSS Inc., Chicago, IL). R software was
used to calculate the cumulative incidence, considering the presence of
competing risk.
RESULTS
Patient Characteristics and Transplantation Outcomes
Therewere 10 children (younger than 16 years of age) and
30 adults (older than 16 years) in this cohort. Patient char-
acteristics are shown in Table 1. The transplantation outcome
was consistent with the results of a previously reported
multicenter trial, as described in detail [8] (Table S1).
Prognostic Value of MLL Gene Expression Level at the
Time of HSCT
Of the 45 patients with MLL-rearranged AL, 35 under-
went analysis by RQ-PCR to detect MLL expression at the
time of allo-HSCT. The association between the status of
MLL expression and the clinical outcomes was evaluated for
these patients. Detectable MLL expression at any level
(MLL > .0000%) was deﬁned as MLL positivity.
Of these 35 patients, 11 were MLL positive before
receiving the conditioning regimen, with a median of 4.320%
of MLL rearrangement at the molecular level, as determined
by RQ-PCR (range, .012% to 25.3%). Five of the 11 patients
relapsed, compared with 2 of the remaining 24 patients with
noMLL expression at the time of relapse after allo-HSCT. The
3-year cumulative relapse frequencies (CIR) of the ML-
positive and -negative groups were 45.5% and 8.3%, respec-
tively (P ¼ .003). The median time to relapse of the MLL
positive group was 314 days (range, 116 to 408 days). The 3-
year LFS and OS of theMLL-positive andMLL-negative groups
were 27.3% versus 79.2% (P ¼ .003) and 36.4% versus 83.3%
(P ¼ .001), respectively (Figure 1).
Prognostic Value of MLL Expression after HSCT
A total of 9 patients had detectable MLL expression after
HSCT during the follow-up period, with a median of 1.300%
(range, .0037% to 16.5%) occurring at a median of 100 days
(range, 30 to 610 days) after transplantation. Five of the 11
patients who were positive at the time of transplantation
were determined to be MLL positive after HSCT. In contrast,
4 of the 24 patients who were negative at the time of
transplantation were found to be MLL positive after HSCT. At
1 and 2 months after HSCT, MLL positivity was detected in
J. Liu et al. / Biol Blood Marrow Transplant 20 (2014) 929e936932only 2 patients. At 3 months, MLL positivity was detected in
another 3 patients. At 4 and 5 months, 3 additional patients
becameMLL positive. The impact of theMLL expression after
HSCT on the clinical outcomes was evaluated for 40 patients
with MLL-rearranged AL after HSCT.
The LFS, OS, and CIR were compared between patients
who were MLLþ or MLL- after transplantation. The 3-year
CIR of patients who were MLL positive (MLL > .0000%)
(n ¼ 9) after HSCT was 93.5% (95% CI, 87% to 100%)
compared with 12.5% (95% CI, 5.6% to 19.4%) for MLL-
negative patients (n ¼ 31) (P < .001). For these 2 groups,
the 3-year OS was 12.5% (95% CI, .8% to 24.2%) and 77.8%
(95% CI, 68.4% to 87.2%), respectively (P < .001); the 3-year
LFS was 0% and 72.2% (95% CI, 61.1% to 83.3%), respectively
(P < .001) (Figure 2B-D). We performed a receiver operating
characteristic (ROC) analysis to evaluate the association
between relapse and the highest level of expression of MLL
before hematological relapse after HSCT in all patients. The
area under the ROC curve value was .897 (95% CI, .744 to
1.000; P ¼ .000) (Figure 2A). These results indicate that MLL
expression is a sensitive and speciﬁc biomarker for pre-
dicting relapse of AL after HSCT.
As most MLL positivity emerged at 3 and 4 months after
HSCT (7 of 9, 77.8%), we evaluated the prognostic value at
these 2 time points. For patients who developed MLL pos-
itivity at 3 months after HSCT (n ¼ 4), the 3-year CIR was
100% (95% CI, 89.7% to 100%) compared with 12.1% (95% CI,
7.4% to 16.8%) for the MLL-negative patients (n ¼ 35) (P <
.001). The 3-year OS for the 2 groups was 25% (95% CI, 13.5%
to 36.5%) and 70.2% (95% CI, 61.4% to 79%), respectively
(P < .001); the 3-year LFS was 0% (95% CI, 0% to 11.2%) and
67.6% (95% CI, 58.3% to 76.9%), respectively (P < .001). ForFigure 2. (A) ROC analysis ofMLL expression and rate of relapse. (B) The rate of relapse
after allo-HSCT based on MLL expression (P < .001). (D) Overall survival after allo-HSpatients who developed MLL positivity at 4 months after
HSCT (n ¼ 6), the 3-year CIR was 100% (95% CI, 88.4% to
100%) compared with 9.4% (95% CI, 1.3% to 17.5%) for MLL-
negative patients (n ¼ 33) (P < .001). The 3-year OS for
these 2 groups was 16.7% (95% CI, 7.5% to 15.9%) and 75%
(95% CI, 66.6% to 83.4%), respectively (P < .001); the 3-year
LFS was 0% (95% CI, 0% to 10.2%) and 71.9% (95% CI, 63.3% to
80.2%), respectively (P < .001).
The Predictive Value of Sequential Monitoring of MRD
The predictive value of sequential monitoring of MRD by
RQ-PCR in BM specimens was demonstrated in the 9 patients
with relapse (Figure 3). Themedian time from thedetection of
MRD positivity in the BM samples to hematological relapse
was 109 days (range, 44 to 305 days). Among those 9 patients,
4 had received prophylactic DLI before the development of
positiveMRD,2 receivedDLI for thedetectionof positiveMRD,
and the other 2 did not receive DLI because of the nonavail-
ability of donor cells. The level of MLL expression before
relapse had awide intra- and interindividual range: 4 of the 9
patients (patients 4, 7, 14, and 24) demonstrated amonthly 1-
to 2-log increase of MLL expression before hematologic
relapse,1 patient (patient 34) relapsed quickly after detection
of a very low MLL expression (.001% to .01%) twice, whereas
the other 3 patients (patients 2, 15, and 22) experienced a
decrease ofMLL expression before hematologic relapse.
The Impact of MRD Status after HSCT on Relapse, OS, and
LFS in Multivariate Analysis
We analyzed other variables that may affect the outcome
of transplantation including the patients’ age, sex, HLA
match, status of the disease before HSCT (CR1 versusbased onMLL expression after allo-HSCT (P < .001). (C) Leukemia-free survival
CT based on MLL expression (P < .001).
Figure 3. Sequential monitoring of MRD in bone marrow specimens. The levels of MRD in consecutive bone marrow samples are shown for 9 patients with a relapse
of AL after allo-HSCT.
J. Liu et al. / Biol Blood Marrow Transplant 20 (2014) 929e936 933non-CR1), WBC at diagnosis, and use of prophylactic DLI. The
results of univariate analyses were shown in Table 2. Factors
with P values < .05 were included in the subsequent Cox
multivariate analysis. The association between MLL expres-
sion and relapse was then analyzed using a Cox multivariate
analysis that included the status of disease before HSCT (CR1
versus non-CR1), prophylactic DLI, and MLL expression
before and after HSCT. Interestingly, only MRD positivity
after allo-HSCT was associated with a higher rate of relapse
(HR, 18.643; 95% CI, 3.449 to 57.025; P ¼ .001). CoxTable 2
Univariate Analysis of the Variables Affecting Hematological Relapse, TRM,
LFS, and OS in Patients with MLLþ AL after Allo-HSCT
Variables TRM Relapse OS LFS
P Value P Value P Value P Value
Age of recipient
35 y .112 .938 .306 .675
<35 y
Underlying disease
AML .241 .886 .387 .432
ALL
Pretransplantation disease status
CR1 .161 .013 .001 .005
Non-CR1
Infused nuclear cells (108/kg)
7.78 .138 .269 .034 .042
<7.78
HLA disparity
0/1/2/3 .432 .868 .706 .761
WBC at diagnosis, 109/L
30 .439 .493 .441 .603
<30
ABO compatibility
Compatible .867 .274 .860 .639
Incompatible
Diagnosis to treatment interval, d
180 .652 .097 .162 .08
<180
Prophylactic DLI .504 .046 .098 .086
Pretransplantation MLL
MLL > .000% .299 .043 .032 .004
MLL ¼ .000%
Post-transplantation MLL
MLL > .000% .326 < .001 < .001 < .001
MLL ¼ .000%
TRM indicates transplantation-associated mortality; CIR, cumulative inci-
dence of relapse; LFS, leukemia-free survival; OS, overall survival; d, day;
allo-HSCT, allogeneic hematopoietic stem cell transplantation; DLI, donor
lymphocyte infusion; MLL, mixed lineage leukemia; AL, acute leukemia.multivariate analysis was also performed to investigate the
impact of MLL expression after HSCT on LFS and OS. Only
MRD positivity after allo-HSCTwas associatedwith lower LFS
(HR, 8.259; 95% CI, 2.109 to 32.336; P ¼ .002) and OS (HR,
7.267; 95% CI, 2.038 to 25.916; P ¼ .002) (Table 3).Comparison of MLL Expression with Wilms Tumor Gene
and MRD Monitored by Four-color FCM after Allo-HSCT
In the 40 patients with AL, monitoring of MRD was also
performed concurrently using 4-color FCM for leukemia-
associated aberrant immune phenotypes and RQ-RCR for
Wilms tumor (WT1) gene expression. The results obtained
from thesemethodswere then compared.WT1 positivity and
FCMpositivity were deﬁned according to previously reported
data [23,24]. BothWT1 expression andmonitoring ofMRD by
FCM showed a signiﬁcant association with relapse (P < .001
and P ¼ .036), respectively. Eleven of the 27 MLL-positive
sampleswere also positive forMRD by FCM,whereas 4 of 203
MLL-negative samples were positive by FCM. A nonpara-
metric Spearman analysis showed a signiﬁcant correlation
between MLL expression and MRD monitoring by FCM
(Spearman r ¼ .397; P ¼ .032). All 27 MLL-positive samples
wereWT1 positive in this study, whereas the 9WT1-positive
samples were MLL negative. There was a good concordance
between the levels of MLL and WT1 expression (Spearman
r ¼ .404; P < .001). In this cohort of patients with MLLþ AL
undergoing allo-HSCT, the expression of the MLL gene had
a higher speciﬁcity and sensitivity than WT1 or MRD
monitored by FCM in predicting hematological relapse
(Table 4).Table 3
Multivariate Analysis of the Variables Affecting Hematological Relapse, TRM,
LFS, and OS in Patients with MLLþ AL after allo-HSCT
Outcome HR 95% CI P Value
Relapse
MLL positive 18.643 3.449-57.025 .001
OS
MLL positive 8.259 2.109-32.336 .002
LFS
MLL positive 7.267 2.038-25.916 .002
LFS indicates leukemia-free survival; OS, overall survival; allo-HSCT, allo-
geneic hematopoietic stem cell transplantation; MLL, mixed lineage leuke-
mia; AL, acute leukemia; HR, hazard ratio; CI, conﬁdence interval; TRM,
treatment-related mortality.
Table 4
Comparison of the Sensitivity and Speciﬁcity for Predicting the Recurrence
of Leukemia by Assessing MLL, WT1, or FCM by RQ-PCR
Relapse (n ¼ 9) No Relapse (n ¼ 31)
MLL positive/negative 8/1 1/30
WT1 positive/negative 7/2 7/24
FCM positive/negative 5/4 4/27
MLL indicates mixed lineage leukemia; FCM, ﬂow cytometry; RQ-PCR, real-
time quantitative polymerase chain reaction; WT1, Wilms tumor gene.
J. Liu et al. / Biol Blood Marrow Transplant 20 (2014) 929e936934The Distribution and Impact of MLL Rearrangement on
Clinical Outcome after HSCT in Different Subgroups of
Patients
The distribution and impact of the MRD status after HSCT
on relapse, OS, and LFS were analyzed separately in sub-
groups of patients of and ages with different underlying
diseases (Table 5). There were no signiﬁcant differences be-
tween patients with AML and ALL. Nevertheless, the ratio of
MLL positivity in children was less than in adults. Nonpara-
metric Spearman analysis showed a signiﬁcant correlation
between MLL expression and MRD monitoring by FCM in
both AML (Spearman r ¼ .279; P ¼ .048) and ALL (Spearman
r ¼ .352; P ¼ .041) subgroups.DISCUSSION
In the present prospective study, we investigated the
prognostic value of MLL expression in patients with MLL-
rearranged AL undergoing allo-HSCT. To our knowledge, our
study is the ﬁrst report that examines the subgroups of pa-
tients with MLLþ AL treated uniformly with HSCT. In this
report, we demonstrated that MLL expression may help
identify patients at high risk of relapse of leukemia after allo-
HSCT.
Accumulating evidence has shown that PCR-based
MRD monitoring after HSCT is an essential predictor of
the outcome in patients with AL [25-28]. Nevertheless, the
prognostic value of MRD monitoring targeting MLL-rear-
ranged transcripts in AL has not been extensively studied.
MRD before transplantation was previously evaluated in 37
patients with ALL by RT(RQ)-PCR targeting BCR-ABL1 or the
MLL-AF4 fusion transcripts or by ASO RQ-PCR targeting the
rearrangements of antigen-receptor genes. It was found
that after a median follow-up period of 23 months, the
cumulative incidence of relapse was 46% for MRD-positive
and 0% for MRD-negative patients (P ¼ .027) [25]. Howev-
er, only 2 cases of MLLþ ALL were included in that study.
Hence, the prognostic value of MLL expression was not
sufﬁciently studied. Several studies have emphasized the
prognostic signiﬁcance of the levels of MRD in patients
receiving chemotherapy [14,29,30]. Scholl et al. [29]
evaluated the clinical signiﬁcance of using the RQ-RCR
assay for the quantiﬁcation of MLL-AF9 fusion transcriptsTable 5
The Distribution and Impact of MLL Expression on Three-Year CIR, OS, and LFS afte
MRD Positive
Percentage CIR 0S L
AML 17% 100% 0% 0
ALL 31% 80% 20% 0
Adult 24% 85.7% 0% 0
Children 9% 100% 0% 0
MLL indicates mixed lineage leukemia; CIR, cumulative incidence of relapse; OS, ove
acute lymphoblastic leukemia.for monitoring MRD in 19 patients with MLL-AF9 þ AML
receiving chemotherapy; the authors showed that patients
whose PCR results were positive at least once for CR during
therapy had a signiﬁcantly higher CIR (P ¼ .004) and worse
OS (P ¼ .003) compared with patients maintaining PCR-
negativity in hematologic-complete remission. Weisser
et al. [30] analyzed samples from 44 AML patients with a
partial tandem duplication within the MLL-gene (MLL-PTD)
during follow-up and observed a  2-log reduction of MLL-
PTD expression (in comparison to a < 2-log reduction)
within 6 months after the start of chemotherapy was found
to be signiﬁcantly associated with a longer OS. Unlike other
analyses, our cohort focused on patients with MLLþ AL
treated uniformly with allo-HSCT, and the prognostic value
of monitoring MLL expression before and after HSCT was
evaluated. In agreement with previous observations of
monitoring MRD by assessing BCR/ABL as well as TCR
rearrangements, we showed that MLL positivity both before
and after HSCT had a signiﬁcant impact on relapse, OS, and
LFS, whereas only MLL expression after allo-HSCT was
associated with higher relapse rate, and worse OS and LFS
in Cox multivariate analyses. The results of the ROC analysis
further conﬁrmed that the level of MLL transcript after
transplantation was associated with a higher risk of he-
matological relapse.
Although maximum sensitivity is obviously important in
the detection of MRD, the frequency of monitoring is an
essential variable that is often overlooked. Spinelli et al. [25]
previously reported that for ALL patients with BCR/ABL and
TCR-rearrangements whose MRD status was determined
at þ100 days after transplantation, the relapse rate was
remarkably low (7%) in PCR-negative patients compared
with those who were PCR-positive (80%, P ¼ .0006). In our
cohort,MLL positivity occurred at a median of 100 days after
transplantation and most occurred at 3 and 4 months after
HSCT. Although MRD positivity within the ﬁrst 2 months
after HSCT was rare and insufﬁcient for statistical analysis,
the relapse rate among these MRD-positive patients was
relatively high. These data suggest that MLL positivity at any
time after allo-HSCT should be considered crucial for sub-
sequent therapeutic decisions. Because of the limited num-
ber of cases in the present cohort, we cannot conclude
whether a threshold of absolute level of MLL expression can
predict imminent relapse or whether the slope of increase
(rate of change) inMLL expression is most predictive. Recent
research showed that molecular monitoring of MRD in the
peripheral blood of patients with multiple myeloma was
associatedwith clinical outcome [31]. Jiang Q et al. also found
that the correlations of BCR-ABL transcripts between pe-
ripheral blood and BM specimens were associated with the
molecular response in the BM for chronic myelogenous
leukemia [32]. We wondered whether MLL expression was
detectable in the peripheral blood before relapse. Futurer HSCT in Different Subgroups of Patients
MRD Negative
FS Ratio CIR 0S LFS
% 83% 5% 80% 75%
% 69% 0% 72.7% 72.7%
% 76% 0% 76.2% 76.2%
% 91% 10% 80% 70%
rall survival; LFS, leukemia-free survival; AML, acute myeloid leukemia; ALL,
J. Liu et al. / Biol Blood Marrow Transplant 20 (2014) 929e936 935research focused on this issue may inform the practicality
and necessity of frequent invasive monitoring and provide a
feasible method for a deeper understanding of MLL gene
expression after HSCT.
Modiﬁed DLI was administered to 2 patients without
aGVHD who showed MLL positivity more than once after
HSCT, and prophylactic DLI was administered to a total of 6
patients who were identiﬁed to be at high risk of relapse at
the time of HSCT. Five of these 8 patients relapsed. Although
prophylactic DLI showed no signiﬁcant impact on relapse,
OS, and LFS in the Coxmultivariate analysis, a decrease of 1 to
2 log of MLL expression was observed in 2 patients who
received DLI for intervention after molecular relapse. Thus,
the clinical beneﬁt of MRD-directed DLI and immunosup-
pressive agents withdrawal has yet to be determined and
should be studied in the context of a clinical trial.
Scholl et al. [29] reported a 3-year CIR of approximately
25% and OS of 70% for patients with MLLþ AML who main-
tained PCR-negative MRD during hematological remission
after chemotherapy only. In our cohort, patients with nega-
tive PCR at the time of allo-HSCT had a 3-year CIR of 8.3% and
OS of 79.2%. Clearly, PCR negativity at the time of SCT was
favorable. However, whether these patients could beneﬁt
from allo-HSCT remained to be determined.
In patients with AL undergoing HSCT, MRDmonitoring by
FCM and the level of WT1 expression were independent
prognostic factors that can predict clinical outcomes [23,24].
A correlation between the detection of MLL transcripts and
the FCM results was previously reported in 16 patients with
MLLþ AML receiving chemotherapy. Levels of MLL fusion
transcripts with a cut off value of .05% after chemotherapy, as
well as ﬂowcytometry, could provide prognostic information
in patients with MLLþ AML [33]. We also found signiﬁcant
correlations between the results for MLL and FCM results as
well as the results for MLL and WT1. In addition, it appeared
that the expression of the MLL gene had higher speciﬁcity
and sensitivity than WT1 and MRD monitored by FCM in
predicting relapse in patients withMLLþ AL undergoing allo-
HSCT (Table 4).
In conclusion, our data indicate that MLL expression is a
valuable and essential marker for monitoring MRD in pa-
tients with MLLþ AL after HSCT. The expression of MLL dur-
ing the follow-up period was highly predictive of leukemia
relapse and has better speciﬁcity and sensitivity than WT1
and MRDmonitored by FCM. Although our results need to be
conﬁrmed in a large-scale, prospective study, we consider
the current qualitative assessment of MLL expression to be a
very useful test for the further risk stratiﬁcation of patients to
guide the prevention and management of early hematolog-
ical relapse in patients with MLLþ AL after HSCT. Further
research should address suitable interventions directed by
MRD monitoring after HSCT, which may improve the clinical
outcomes of these patients.
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